1. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Issue 1 (15th September 2021) Authors: Mazza, Stefano; Piazza O. Sed, Nicole; Conforti, Francesco Simone; Fascì, Alberto; Rimondi, Alessandro; Marinoni, Beatrice; Casini, Valentina; Ricci, Chiara; Munari, Francesca; Pirola, Lorena; Invernizzi, Pietro; Girelli, Carlo; Lupinacci, Guido; Pastorelli, Luca; Cavallaro, Flaminia; Ferraris, L... Journal: Clinical and translational science Issue: Volume 15:Issue 1(2022) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗